Americans far and wide have been holding a heated debate about the necessity or efficacy the COVID-19 vaccines that have come to market, and have been bickering viciously regarding the government’s right to force us to get one.
Long before COVID-19 was knocking on our door, there was a large and vocal group of Americans who believed that, in their pursuit of freedom, that they have full sovereignty over what went into their bodies. This included government-mandated vaccines.
The development of the coronavirus vaccines only served to fuel the discussion, and there are concerns among some health officials that a large swatch of the American public are being misinformed about this inoculation.
Now, just days after the Biden administration stated that every willing adult in the nation could be able to be vaccinated as early as the end of May, a new pill is coming to market that could change the game.
A new possible medication to treat coronavirus-positive patients could be enough to turn the pandemic on its head, Fox News medical contributor Dr. Marc Siegel revealed Sunday on “Fox & Friends Weekend.”
First-stage testing of the experimental COVID-19 pill called Molnupiravir, by Merck and Ridgeback Biotherapeutics, showed promising signs of effectiveness in reducing the virus in patients.
“It may be the holy grail on this because it was just studied in phase two trials and it literally stopped the virus in its tracks,” he explained. “And there wasn’t any virus found in the patients that were studied.”
And you wouldn’t even need to be hospitalized in the process.
The drug would function as an at-home, five-day treatment, similar to Tamiflu, to stop the virus from reproducing before causing major damage. Siegel said the therapeutic could come to market in as little as four to five months.
The revolutionary treatment may be just what we need to boost our herd immunity and still allow those wary of the vaccine to avoid getting jabbed.
Become an insider!
Sign up for our free email newsletter, and we'll make sure to keep you in the loop.